Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.96 |
| ▸ | RAB9A | P51151 | 2/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.96 |
| ▸ | HPGD | P15428 | 1/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424631 | 1.00 | NPC1 (0.96) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| Formaldehyde SCHEMBL27861058 | 0.95 | NPC1 (0.87) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL28019337 | 0.87 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL7512518 | 0.82 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL2428264 | 0.78 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL2425683 | 0.75 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL29546942 | 0.74 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL28244373 | 0.74 | HPGD (0.56) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL28283630 | 0.74 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL29546679 | 0.73 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| EP-4137124-B1 | SOLID PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2026-02-25 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3781315-B1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HIFIBIO SAS (FR) | 2026-01-14 | — | — | EP | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4289834-B1 | TETRAHYDROPYRROLOCYCLIC COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC (CN) | 2025-11-26 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4066893-B1 | 6,7,8,9-TETRAHYDRO-4H-QUINOLIZIN-4-ONE COMPOUND AS OREXIN TYPE 2 RECEPTOR AGONIST | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-30 | — | — | EP | claimed |
| EP-3917616-B1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-11 | — | — | EP | claimed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | claimed |
| EP-3984537-B1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-03-20 | — | — | EP | claimed |
| EP-3865212-B1 | MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION | UNIV BRITISH COLUMBIA (CA) | 2024-03-13 | — | — | EP | claimed |
| EP-3895707-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-04 | — | — | EP | claimed |
| EP-3125893-B1 | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS | INTRA CELLULAR THERAPIES INC (US) | 2023-09-20 | — | — | EP | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4518853-A4 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4734999-A1 | METHOD OF TREATING DEPRESSION USING SELTOREXANT | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2022040058-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040070-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040070-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |